Looking for retatrutide for laboratory research? See it at OXpeptides (research use only)
Retatrutide Peptide
Editorial policy

Editorial policy

Seven rules, applied to every page. They exist so that a reader can check anything on this site in under a minute.

Effective 21 September 2026Last reviewed 21 September 2026
The verification chain used on this siteFour linked steps: claim, source with DOI or NCT number, automated check against CrossRef or ClinicalTrials.gov, publication with the source on the same page.ClaimDOI or NCTAPI checkPublished with source
The verification chain: every claim carries a DOI or NCT number that is machine-checked before the page is published.

1. Sourcing

Clinical claims cite peer-reviewed publications by DOI or trial registry records by NCT number. Results that exist only as company announcements are cited by URL and labelled as topline or unpublished. Secondary news coverage is not used as a source for numbers.

2. Verification

Every DOI is resolved against https://api.crossref.org and every NCT number against https://clinicaltrials.gov/api/v2 before publication and at each update. A source that does not resolve is removed along with the claim it supported.

3. Evidence labelling

Phase, sample size, duration and endpoint are stated with each result. Cross-trial comparisons are marked as such and never presented as head-to-head findings.

4. Dosing language

Doses appear only as the protocol of a cited trial. The site never suggests a dose, a schedule, a reconstitution method or a route of administration for personal use. Retatrutide is investigational and not approved by the FDA or the EMA; every page says so.

5. Independence

The site carries no advertising, no sponsorship and no affiliate links. The single supplier link on each article, to the RP listing at OXpeptides (https://oxpeptides.com/products/rp), is unpaid and labelled research use only. No supplier reviews or influences content.

6. People

No testimonials, reviews, before-and-after accounts or invented personas. Discussion of online communities describes patterns of claims without quoting or identifying individuals. No author biographies are fabricated; the site is published as an editorial project, not under a personal byline.

7. Updates and corrections

Each page shows its publication and last update dates. Regulatory status and phase 3 results are reviewed when Lilly, the FDA or the EMA issue a statement. Corrections can be requested at editor@retatrutide-peptide.com; substantive corrections are noted on the page. Read about this site for the method in full, or return to the main guide.